Collectively, the studies highlight the association between mutations in BTK or PLC-g2 and ibrutinib resistance and reinforce the importance of this signalling pathway in the pathogenesis of CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.